Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-acting risperidone injection.

Raymond C Love1, Robert J Conley

  • 1Department of Pharmacy Practice and Science, School of Pharmacy, University of Maryland, Baltimore 21201, USA. rlove@rx.umaryland.edu

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|October 7, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitigating Weight Gain Side Effects by Reducing Sugar-Sweetened Beverage Consumption in Youth Newly Prescribed Second-Generation Antipsychotic Medication.

Nutrients·2026
Same author

A Randomized Controlled Trial of an Extension for Community Healthcare Outcomes (ECHO) Tele-mentoring Program to Increase Clozapine Utilization.

Schizophrenia bulletin·2025
Same author

FDA Eliminates the Clozapine REMS-What Comes Next?

JAMA psychiatry·2025
Same author

A call to action for adverse drug event (ADE) detection and prevention.

Frontiers in digital health·2025
Same author

Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I: A Review of the Pharmacokinetic Literature and Proposed Changes.

Journal of clinical psychopharmacology·2025
Same author

Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II: A Review of Fatal Outcomes in US Pharmacovigilance Data and Proposed Changes.

Journal of clinical psychopharmacology·2025
Same journal

Recent and anticipated novel drug approvals (Q2 2026 through Q1 2027).

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Optimizing transitions from direct factor Xa inhibitors to unfractionated heparin therapy.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Impact of pharmacist involvement on hospital sepsis response teams.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Attributes of centralized health-system specialty pharmacy clinics: A scoping review using the Donabedian model.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Zoliflodacin: A novel single-dose oral antibiotic for uncomplicated urogenital gonorrhea.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Implementation of a paid apprenticeship-model pharmacy technician training program.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
See all related articles

Long-acting risperidone injection, the first atypical antipsychotic injectable, shows efficacy and tolerability in schizophrenia patients. It offers sustained drug levels and improved quality of life with similar side effects to oral forms.

Area of Science:

  • Pharmacology and clinical science
  • Psychiatry
  • Drug development

Background:

  • Long-acting injectable formulations offer potential advantages for medication adherence in chronic conditions.
  • Risperidone is an atypical antipsychotic used for schizophrenia and schizoaffective disorder.

Purpose of the Study:

  • To review the pharmacology, pharmaceutics, clinical efficacy, adverse effects, cost, and administration of long-acting risperidone injection.
  • To evaluate the safety and tolerability of this formulation in patients with schizophrenia and schizoaffective disorder.

Main Methods:

  • Review of existing literature on long-acting risperidone injection.
  • Analysis of data from a 12-week double-blind placebo-controlled study.
  • Evaluation of a one-year open-label study.

Related Experiment Videos

Main Results:

  • Long-acting risperidone injection achieves sustained therapeutic plasma levels for 6 weeks after a single dose.
  • Clinical studies demonstrated efficacy, safety, and tolerability in schizophrenia and schizoaffective disorder patients.
  • Adverse effect rates were similar to placebo, with comparable weight gain to oral risperidone. Improvement in extrapyramidal symptoms and reduction in prolactin levels were observed.

Conclusions:

  • Long-acting risperidone injection is the first atypical antipsychotic available in a long-acting injectable formulation.
  • It provides assured medication delivery, potentially improving long-term outcomes for schizophrenia patients.
  • The formulation demonstrates favorable tolerability and efficacy, offering a valuable treatment option.